Endpoints News 生物医药· Max Gelman·· 5 天前AI 评分55
FDA拒绝Summit和Akeso的肺癌治疗药物申请
FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting
AI 导读
FDA拒绝Summit和Akeso的肺癌治疗药物ivonescimab的申请,分析师认为这不会影响该药物的市场前景。
正文
The FDA rejected a new cancer treatment from Summit Therapeutics and Akeso in a decision that analysts largely expected, but ultimately shouldn’t dim the prospects …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news